COMMUNIQUÉS West-GlobeNewswire

Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994
04/02/2019
CAMBRIDGE, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in [...]
Canopy Rivers Announces Completion of $17 Million Financing for Its Italian Hemp Platform - Canapar
04/02/2019
TORONTO, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (the “ Company ” or “ Canopy Rivers ”) (TSXV: RIV) is pleased to announce that it has completed a subsequent $9.4 million equity investment in its portfolio [...]
Radient Technologies Inc. Announces Changes to its Board of Directors and Provides Corporate Update
04/02/2019
EDMONTON, Alberta, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI; OTCQX: RDDTF ) announces today the following changes to its Board of Directors. The Company [...]
Evolus to Hold Conference Call Following Jeuveau™ FDA Approval
04/02/2019
Conference Call Scheduled for at 8:00am ET / 5:00am PT NEWPORT BEACH, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), today announced that members of management will host a conference call today, [...]
Fennec Pharmaceuticals Announces $12.5 Million Debt Financing With Bridge Bank
04/02/2019
RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM (a unique formulation of [...]
Crescita Therapeutics Inc.™ and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra’s Dermatology Product Portfolio
04/02/2019
LAVAL, Quebec, and ORLEANS, Ontario, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Crescita Therapeutics Inc. ("Crescita") (TSX: CTX), a Canadian commercial dermatology company and Tetra Natural Health (NHP), a subsidiary of Tetra [...]
Orion intents to start an open label extension study to the REFALS phase 3 trial studying the effect of oral levosimendan in patients with ALS
04/02/2019
Orion Corporation Press release 4 February 2019 at 10.00 a.m. EET Orion intents to start an open label extension study to the REFALS phase 3 trial studying the effect of oral levosimendan in patients with ALS Orion [...]
Aino Health AB (publ): Aino Health's solution go-live for Multi Contact GmbH
04/02/2019
2019-02-04 Aino Health go-live with its SaaS solution Aino HealthManager for Multi Contact's operations in Germany. This is a joint implementation project with MultiContact and Aino Health that is comprised of process [...]
Aino Health AB (publ): Aino Health's solution go-live for Multi Contact GmbH
04/02/2019
2019-02-04 Aino Health go-live with its SaaS solution Aino HealthManager for Multi Contact's operations in Germany. This is a joint implementation project with MultiContact and Aino Health that is comprised of process [...]
Aino Health AB (publ): Aino Health's solution go-live for Multi Contact GmbH
04/02/2019
2019-02-04 Aino Health go-live with its SaaS solution Aino HealthManager for Multi Contact's operations in Germany. This is a joint implementation project with MultiContact and Aino Health that is comprised of process [...]
Oxurion NV to Present at the 2019 BIO CEO & Investor Conference
04/02/2019
Leuven, Belgium, 4 February 2019 - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced [...]
Verona Pharma to Present at Upcoming Investor Conferences
04/02/2019
LONDON, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]
Curetis’ Partner Beijing Clear Biotech Submits Filing for Unyvero Approval in China
04/02/2019
Curetis’ Partner Beijing Clear Biotech Submits Filing for Unyvero Approval in China Submission for Unyvero HPN Cartridge to Chinese regulatory authority NMPA includes U.S. and EU data Leverages recent changes in [...]
Sanofi: CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease
04/02/2019
CHMP recommends approval of Praluent ® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease PARIS and TARRYTOWN, NY - February 4, 2019 - The European Medicines [...]
Sanofi : Le CHMP recommande l'approbation de Praluent® (alirocumab) pour la réduction du risque cardiovasculaire chez les personnes atteintes de maladie cardiovasculaire athéroscléreuse établie
04/02/2019
Le CHMP recommande l'approbation de Praluent ® (alirocumab) pour la réduction du risque cardiovasculaire chez les personnes atteintes de maladie cardiovasculaire athéroscléreuse établie Paris et Tarrytown (New York) - [...]
argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology
04/02/2019
argenx gains access to ENHANZE® subcutaneous delivery technology for up to three targets, including exclusive rights to develop therapeutic products targeting human neonatal Fc receptor FcRn February 4, 2019 Breda, the [...]
CROSSJECT : Financement de 1,1 M€ accordé conjointement par Bpifrance et la région Bourgogne-Franche Comté
04/02/2019
Communiqué de Presse Financement de 1,1 M€ accordé conjointement par Bpifrance et la région Bourgogne-Franche Comté Dijon, le 4 février 2019 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui [...]
Nancy J. Sandy nommée directrice générale de Taconic Biosciences
01/02/2019
RENSSELAER, NY, 01 févr. 2019 (GLOBE NEWSWIRE) -- Le conseil d’administration de Taconic Biosciences a choisi Nancy J. Sandy pour succéder à M. Robert J. Rosenthal au poste de directeur général (DG). Mme Sandy est à la [...]
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/02/2019
BURLINGTON, Mass., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to 14 new employees for an aggregate of 51,000 shares of common stock. [...]

Pages